XLON
THAT
Market cap7mUSD
Apr 13, Last price
0.68GBP
Name
N4 Pharma PLC
Chart & performance
P/E
—
P/S
771.48
EPS
—
Div yield, %
—
Shrs. gr., 5y
27.75%
Rev. gr., 5y
-60.78%
Revenues
7k
+272.86%
Net income
-1m
L-16.55%
CFO
-972k
L-19.65%
Dividend
May 19, 19970.45 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
N4 Pharma Plc is a specialized pharmaceutical company dedicated to creating advanced silica nanoparticle delivery platforms for pharmaceutical and biotechnology organizations throughout the United Kingdom. A core product is Nuvec, a non-viral adjuvant delivery system specifically designed for use in vaccine development and cancer therapies. Founded in 1979, the company is headquartered in London, UK.
Key people
Non-Executive Chairman of the Board · since 2019
David Templeton
Executive Director · since 2019
Nigel James Theobald
Chief Executive Officer, Executive Director
Chris Britten
Non-Executive Director · since 2019
Non-Executive Director · since 2015
Headquarters & legal address
C/O ARCH LAW HUCKLETREE BISHOPSGATE
8 BISHOPSGATE
LONDON, LND EC2N 4BQ
GB
8 BISHOPSGATE
LONDON, LND EC2N 4BQ
GB
Previous name
ONZIMA VENTURES PLC
Previous name
ULTIMA NETWORKS PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||